Neuro-Oncology: Brain & Spinal Tumour Care in Malaysia

Neuro-oncology is not simply brain tumour surgery. It is the discipline that sits at the intersection of neurosurgery, medical oncology, radiation oncology, and neuropathology — bringing these specialties together around a single patient with a single diagnosis that changes their life in an instant.

I have spent the last two decades building a practice centred on this intersection. My DPhil at the University of Oxford thought me to think and act outside the box of surgery and oncology. My clinical training spans high-volume neuro-oncology at the University of Malaya Medical Centre — one of Southeast Asia’s busiest neurosurgical centres — to focused specialist practice at KPJ Tawakkal Specialist Hospital in Kuala Lumpur.

This page explains what neuro-oncology means in practice, what it means for you as a patient, and how I approach it.

What Is Neuro-Oncology?

Neuro-oncology is the medical subspecialty dedicated to tumours of the brain, spinal cord, and the nerves that serve them. It encompasses:

• Surgical neuro-oncology — the safe removal, debulking, or biopsy of central nervous system tumours
• Medical neuro-oncology — chemotherapy and targeted therapy for brain tumours
• Radiation neuro-oncology — stereotactic radiosurgery, fractionated radiotherapy, and proton therapy for brain and spinal tumours
• Neuropathology — tumour classification by histology and molecular profile, which determines everything that follows

No single specialist can provide all of this. What a neuro-oncology neurosurgeon provides is the surgical expertise and the clinical leadership to coordinate the rest — ensuring that the patient navigating this system has an advocate who understands all four disciplines.

Brain and Spinal Tumours I Treat

Primary Brain Tumours

Gliomas (Grade 1–4) The most common group of primary brain tumours, arising from glial cells — the brain’s support network. Low-grade gliomas (Grade 2) grow slowly but carry malignant potential. High-grade gliomas, including glioblastoma (GBM, Grade 4), are aggressive and require maximal safe resection followed by the Stupp protocol of concurrent chemoradiation and adjuvant temozolomide.

→ Full guide: Glioma & Glioblastoma

Meningioma The most common benign brain tumour. Arises from the meninges — the protective covering of the brain. Most are Grade 1 and curable with surgery alone. Recurrent or atypical meningiomas (Grade 2–3) may require adjuvant radiation.

→ Full guide: Meningioma

Pituitary Adenoma Tumours at the base of the brain disrupting hormonal regulation. Often resectable through minimally invasive endonasal (transnasal) surgery — no scalp incision required.

Acoustic Neuroma (Vestibular Schwannoma) Benign tumour on the vestibulocochlear nerve causing hearing loss, tinnitus, and balance disturbance. Managed with surgery, stereotactic radiosurgery, or observation depending on size and rate of growth.

Medulloblastoma The most common malignant brain tumour in children. Arises in the posterior fossa. Highly treatment-sensitive — surgical resection followed by risk-stratified chemoradiation achieves long-term remission in many patients.

→ Full guide: Paediatric Brain Tumour

Primary CNS Lymphoma A rare but aggressive lymphoma confined to the brain and spinal cord. Surgery plays a limited role — typically biopsy only. Treatment is primarily high-dose methotrexate-based chemotherapy. Tissue diagnosis is essential.

Brain Metastases

Cancer that has spread to the brain from a primary tumour elsewhere — most commonly lung, breast, colon, melanoma, or renal cell carcinoma. Brain metastases are more common than primary brain tumours. They may be single or multiple, symptomatic or incidentally discovered.

Surgical resection improves survival and quality of life in patients with:

• Single accessible metastasis with controlled systemic disease
• Large lesions causing significant mass effect
• Unknown primary (for tissue diagnosis)
• Radiation-resistant histology (renal cell carcinoma, melanoma)

I work closely with the oncology team at KPJ Tawakkal to ensure systemic disease control and surgical decisions are made together — not in isolation.

Spinal Tumours

The spinal cord is as surgically demanding as the brain, and spinal tumours are no less life-altering. I treat:

• Spinal cord tumours (intramedullary) — ependymoma, astrocytoma arising within the cord itself
• Intradural extramedullary tumours — meningioma, nerve sheath tumours (schwannoma, neurofibroma) growing within the spinal canal outside the cord
• Vertebral / extradural metastases — cancer spreading to the vertebrae and compressing the spinal cord

Spinal cord tumour surgery requires microsurgical precision, intraoperative neuromonitoring, and meticulous understanding of spinal cord anatomy. The margin between tumour and functional spinal tissue is measured in millimetres.

The Molecular Revolution in Neuro-Oncology

The diagnosis of a brain tumour no longer ends at the microscope. Modern neuro-oncology is defined by molecular profiling — genetic and epigenetic markers that determine tumour behaviour, prognosis, and treatment response far more accurately than histology alone.

Key molecular markers I test on every applicable case:

Treatment decisions made without molecular data in 2026 are incomplete. I will not treat your tumour based on what it looks like under the microscope alone.

Surgical Techniques in Neuro-Oncology

Craniotomy with Neuronavigation

All my craniotomies use real-time 3D frameless stereotactic navigation — the neurosurgical equivalent of GPS. Your pre-operative MRI is registered into the navigation system, allowing precise tracking of tumour boundaries and safe corridors throughout surgery.

Awake Craniotomy

For tumours adjacent to eloquent cortex — the speech, language, and motor areas — I perform awake craniotomy. You remain awake and responsive during the critical resection phase. Direct cortical stimulation maps your functional boundaries in real time. This allows significantly greater tumour removal while preserving the functions that matter most to your daily life.

→ More on awake craniotomy in the Brain Tumour Surgery guide

5-ALA Fluorescence-Guided Surgery

For high-grade gliomas, 5-aminolevulinic acid (5-ALA) is taken orally the night before surgery. Glioma cells accumulate its fluorescent metabolite — glowing pink under a specific light wavelength in the operating microscope. This allows me to visualise tumour margins invisible under white light, improving the extent of resection.

Intraoperative Neuromonitoring (IONM)

Continuous monitoring of motor evoked potentials (MEP), somatosensory evoked potentials (SSEP), and electromyography throughout surgery. Any change in signal is an early warning — I pause, reassess, and adjust before permanent deficit occurs.

Minimally Invasive Endoscopic Surgery

For pituitary tumours and select skull base lesions: transnasal endoscopic resection using a 4mm scope through the nose. No scalp incision. Rapid recovery.

Stereotactic Biopsy

For tumours in deep or eloquent locations where open resection is unsafe: frameless needle biopsy for tissue diagnosis with minimal surgical trauma.

Multidisciplinary Tumour Board

A brain tumour diagnosis requires more than one specialist and more than one appointment. At KPJ Tawakkal, I participate in multidisciplinary tumour board review — where neurosurgery, oncology, radiation oncology, and neuropathology review each case together before finalising a treatment plan.

This matters because:

• The surgical decision (what to remove, how much, when) affects the subsequent oncology plan
• The oncology plan affects how quickly surgery needs to happen
• Molecular results from surgery directly determine chemotherapy selection
• Radiation planning requires knowledge of surgical margins

Coordination is not a luxury in neuro-oncology. It is the standard of care.

My Approach to Neuro-Oncology

I will tell you what I know, what I don’t know, and what the evidence says about your specific tumour. I will give you the options, the risks, and the realistic outcomes — not the best-case scenario.

Some things I commit to in every neuro-oncology consultation:

1. I review your MRI personally before we meet. Not a summary. The actual scan.
2. I request full molecular profiling on every resected tumour where it is indicated.
3. I will not recommend surgery if surgery is not the right answer. Some tumours are best managed non-surgically.
4. I will introduce you to the oncology team personally if systemic treatment is needed.
5. I will be available after surgery. The relationship does not end in the operating theatre.

Why Subspecialty Neuro-Oncology Experience Matters

Not every neurosurgeon performs awake craniotomy. Not every neurosurgeon uses 5-ALA. Not every neurosurgeon participates in tumour board. Not every neurosurgeon requests — or knows how to interpret — full molecular profiling.

These are not minor technical differences. They translate directly into:

• More complete tumour resection (which extends survival in GBM)
• Lower rates of post-operative neurological deficit
• Faster access to appropriate adjuvant therapy
• A treatment plan that matches your tumour’s biology rather than its appearance alone

My Oxford DPhil in neuroscience was not a detour from clinical practice. It was the foundation for understanding brain tumour biology at a level that informs every operative decision I make.

Frequently Asked Questions

Q: Is neuro-oncology different from oncology? Yes. Medical oncologists manage systemic chemotherapy and immunotherapy. Neuro-oncologists specialise in tumours of the central nervous system, which behave differently, are harder to reach, and respond to treatment differently from other cancers. Surgical neuro-oncology is the branch that manages surgical access, resection, and biopsy — the foundation that makes subsequent treatment possible.

Q: Do I need to see a neuro-oncologist and a neurosurgeon separately? In the ideal system, yes — and this is how it works at KPJ Tawakkal. I manage the surgical component. The neuro-oncology physician manages adjuvant therapy. We coordinate through tumour board and direct communication so you are not left to bridge the gap yourself.

Q: My tumour is inoperable. Is there still a role for surgery? Often, yes. Even for tumours where complete resection is not achievable — deep gliomas, brainstem lesions, multiple metastases — surgery in the form of stereotactic biopsy provides the tissue diagnosis that unlocks targeted chemotherapy, immunotherapy, or clinical trial enrolment. No tissue, no targeted treatment.

Q: What is the difference between a malignant and a benign brain tumour? Malignancy refers to the tumour’s ability to invade surrounding tissue and spread. Benign tumours do not spread, but they are not harmless — a benign meningioma compressing the brainstem is a life-threatening emergency. Location, size, and rate of growth matter as much as malignant potential in determining urgency of treatment.

Q: Can brain tumours recur after surgery? Yes. Recurrence rates depend entirely on tumour biology. Grade I meningioma recurs in fewer than 5% of cases after complete resection. Glioblastoma virtually always recurs — the question is when, and how to extend the time to recurrence. This is why long-term MRI surveillance is not optional — it is built into the treatment plan from day one.

Q: Should I seek a second opinion before proceeding with surgery? Yes. I encourage it. For any brain tumour surgery — elective or urgent — a second opinion from a neurosurgeon with neuro-oncology experience is entirely appropriate. Come to me for a second opinion. I will tell you honestly what I see.

Book a Neuro-Oncology Consultation

If you or a family member has received a brain or spinal tumour diagnosis — or has imaging that raises concern — contact the clinic to arrange a consultation. Bring your MRI on CD or USB. I review every scan personally before we meet.

WhatsApp the clinic: +6011-3723 5061 Book online: KPJ Tawakkal Appointment Portal Call the clinic: +603-4026 7777 ext 5099

KPJ Tawakkal Specialist Hospital, Jalan Pahang Barat, Kuala Lumpur.

This page is written for educational purposes and does not constitute medical advice. Every tumour is different — diagnosis and treatment decisions must be made in direct consultation with a qualified specialist after review of your specific imaging and pathology.